As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first ...

The growth and complexity of biosimilar agents for infusion therapy is generating a need for effective tools to optimize product selection and manage costs. Frequent changes in payer policies lead to ...

Biologic copycats are making a bigger impact on drug prices as U.S. regulators open the doors wider, and new guidance could ...

Most shoppers are familiar with CVS Health’sCVS-1.09%decrease; red down pointing triangle many private-label products, from women’s daily multivitamins to heart-healthy trail mix. There is a reason ...

In the U.S., Alvotech’s biosimilar to Johnson & Johnson's blockbuster immunology drug Stelara is set to face market competition from the likes of Amgen, Sandoz and Fresenius Kabi. But elsewhere, ...

CVS Health Inc. CVS on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to biosimilar medications, announcing new formulary changes that will take ...

With its biosimilars business thriving, Amgen is in a unique position to comment on U.S. biosimilar policy as the current administration introduces reforms to increase the availability of the copycat ...

The FDA's draft guidance could streamline biosimilar approval by reducing the need for comparative efficacy studies, emphasizing analytical assessments instead. This approach may lower development ...